Wire · opportunities
J&J's Caplyta hits primary endpoint in bipolar mania, supporting FDA filing
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 November 2026 · Fusion42 review
Johnson & Johnson's Caplyta (lumateperone) demonstrated positive efficacy in a second pivotal Phase III trial for bipolar I manic episodes, showing significant symptom reduction versus placebo and supporting an upcoming FDA filing for this new indication.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 11 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
You need to watch how approval of Caplyta for bipolar mania shifts treatment options in mental health. This FDA move opens a door to provide a broader therapy and challenges current mania drugs.
◆ Coverage
1 source · first reported 11 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics